| $350M | ||
| $172M | ||
| $127M | ||
| $109M | ||
| $107M | ||
| $100M |
Buys | $0 | 0 | 0 |
Sells | $174,161,644 | 37 | 100 |
| Henderson Jane | Chief Financial Officer | 0 | $0 | 13 | $2.09M | $-2.09M |
| Dambkowski Carl | Chief Medical Officer | 0 | $0 | 12 | $10.15M | $-10.15M |
| HENDERSON MICHAEL THOMAS | Chief Executive Officer | 0 | $0 | 11 | $28.39M | $-28.39M |
| Fairmount Funds Management LLC | director | 0 | $0 | 1 | $133.53M | $-133.53M |
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
Over the last 12 months, insiders at Apogee Therapeutics, Inc. have bought $0 and sold $174.16M worth of Apogee Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Apogee Therapeutics, Inc. have bought $25.5M and sold $62.25M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 20,000 shares for transaction amount of $990,775 was made by McKenna Mark C. (director) on 2024‑12‑12.
| 2026-08-05 | Sale | Dambkowski Carl | Chief Medical Officer | 5,500 0.0089% | $134.17 | $737,935 | +0.39% | |
| 2026-07-08 | Sale | HENDERSON MICHAEL THOMAS | Chief Executive Officer | 20,000 0.0325% | $133.63 | $2.67M | +0.52% | |
| 2026-07-01 | Sale | Dambkowski Carl | Chief Medical Officer | 5,500 0.0089% | $132.74 | $730,070 | +1.15% | |
| 2026-06-22 | Sale | HENDERSON MICHAEL THOMAS | Chief Executive Officer | 80,000 0.1292% | $132.54 | $10.6M | +1.26% | |
| 2026-06-22 | Sale | Dambkowski Carl | Chief Medical Officer | 26,400 0.0427% | $132.60 | $3.5M | +1.26% | |
| 2026-06-10 | Sale | HENDERSON MICHAEL THOMAS | Chief Executive Officer | 20,000 0.0326% | $83.38 | $1.67M | +62.21% | |
| 2026-06-03 | Sale | Dambkowski Carl | Chief Medical Officer | 5,500 0.0083% | $78.71 | $432,905 | +59.33% | |
| 2026-05-13 | Sale | HENDERSON MICHAEL THOMAS | Chief Executive Officer | 20,000 0.0316% | $82.09 | $1.64M | +59.16% | |
| 2026-05-06 | Sale | Dambkowski Carl | Chief Medical Officer | 5,500 0.0089% | $84.14 | $462,784 | +57.84% | |
| 2026-05-01 | Sale | Henderson Jane | Chief Financial Officer | 2,000 0.0036% | $82.04 | $164,080 | +64.91% | |
| 2026-04-16 | Sale | Henderson Jane | Chief Financial Officer | 2,000 0.0035% | $90.00 | $180,000 | +46.53% | |
| 2026-04-08 | Sale | HENDERSON MICHAEL THOMAS | Chief Executive Officer | 20,000 0.0354% | $82.58 | $1.65M | +59.47% | |
| 2026-04-01 | Sale | Dambkowski Carl | Chief Medical Officer | 5,500 0.0099% | $84.84 | $466,619 | +7.93% | |
| 2026-04-01 | Sale | Henderson Jane | Chief Financial Officer | 2,000 0.0036% | $85.01 | $170,020 | +7.93% | |
| 2026-03-25 | Sale | Henderson Jane | Chief Financial Officer | 2,000 0.0039% | $85.00 | $170,000 | +15.59% | |
| 2026-03-11 | Sale | HENDERSON MICHAEL THOMAS | Chief Executive Officer | 20,000 0.0362% | $74.78 | $1.5M | +19.03% | |
| 2026-03-04 | Sale | Dambkowski Carl | Chief Medical Officer | 5,500 0.0099% | $71.06 | $390,825 | +22.15% | |
| 2026-03-02 | Sale | Henderson Jane | Chief Financial Officer | 2,000 0.0037% | $70.22 | $140,431 | +24.49% | |
| 2026-02-11 | Sale | HENDERSON MICHAEL THOMAS | Chief Executive Officer | 20,000 0.0351% | $63.35 | $1.27M | +30.97% | |
| 2026-02-04 | Sale | Dambkowski Carl | Chief Medical Officer | 5,500 0.0102% | $65.79 | $361,860 | +31.48% |
| HENDERSON MICHAEL THOMAS | Chief Executive Officer | 995987 1.6096% | $134.53M | 0 | 19 | |
| Fairmount Funds Management LLC | director | 298647 0.4826% | $40.34M | 1 | 1 | +50.02% |
| Henderson Jane | Chief Financial Officer | 173371 0.2802% | $23.42M | 0 | 14 | |
| Dambkowski Carl | Chief Medical Officer | 168498 0.2723% | $22.76M | 0 | 27 | |
| McKenna Mark C. | director | 20000 0.0323% | $2.7M | 1 | 0 | <0.0001% |
$224,662,742 | 52 | 32.03% | $6.15B | |
$11,583,737 | 45 | 49.75% | $6.07B | |
$104,428,685 | 44 | 22.55% | $6.11B | |
$477,065,869 | 34 | 82.05% | $8.1B | |
$103,944,213 | 17 | 5.95% | $7.05B | |
$11,859,102 | 17 | 18.62% | $9.05B | |
$118,094,211 | 15 | 38.32% | $9.66B | |
$9,976,473 | 12 | 29.52% | $9.81B | |
$45,831,857 | 11 | 83.04% | $5.94B | |
$2,477,801 | 11 | 4.98% | $7.73B | |
$762,720 | 11 | 52.96% | $9.65B | |
$35,908,794 | 10 | 126.31% | $9.37B | |
$11,898,979 | 10 | 54.58% | $10.56B | |
$25,064,843 | 9 | 12.75% | $6.63B | |
$55,713,031 | 8 | -0.36% | $8.46B | |
$2,246,813 | 6 | 70.15% | $8.57B | |
$41,376,000 | 4 | -12.07% | $8.83B | |
Apogee Therapeutics, Inc. (APGE) | $50,990,767 | 2 | 19.79% | $8.36B |
$7,600,000 | 1 | -4.05% | $6.59B |
| Increased Positions | 140 | +88.61% | 16M | +26.44% |
| Decreased Positions | 68 | -43.04% | 6M | -9.49% |
| New Positions | 53 | New | 4M | New |
| Sold Out Positions | 20 | Sold Out | 1M | Sold Out |
| Total Postitions | 230 | +45.57% | 70M | +16.95% |
| Vr Adviser, Llc | $643,624.00 | 15.44% | 8.49M | 0 | 0% | 2025-09-30 |
| Fmr Llc | $524,129.00 | 12.58% | 6.92M | +9,362 | +0.14% | 2025-09-30 |
| Wellington Management Group Llp | $357,962.00 | 8.59% | 4.72M | +917,991 | +24.12% | 2025-09-30 |
| Rtw Investments, Lp | $205,523.00 | 4.93% | 2.71M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $203,547.00 | 4.88% | 2.69M | +123,487 | +4.82% | 2025-09-30 |
| Vanguard Group Inc | $170,174.00 | 4.08% | 2.25M | +136,693 | +6.48% | 2025-09-30 |
| Driehaus Capital Management Llc | $163,571.00 | 3.93% | 2.16M | -152,253 | -6.59% | 2025-09-30 |
| Fairmount Funds Management Llc | $155,246.00 | 3.73% | 2.05M | 0 | 0% | 2025-09-30 |
| State Street Corp | $125,457.00 | 3.01% | 1.66M | +396,290 | +31.47% | 2025-09-30 |
| Paradigm Biocapital Advisors Lp | $115,319.00 | 2.77% | 1.52M | +563,127 | +58.74% | 2025-09-30 |